Challenges translating breast cancer gene signatures into the clinic

Nature Reviews Clinical Oncology

Volumn 9, Issue 1, 2012, Pages 58-64

  Weigelt, Britta ^a   Pusztai, Lajos ^b   Ashworth, Alan ^c   Reis Filho, Jorge S ^c  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CRIZOTINIB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; GEFITINIB; MESSENGER RNA;

ACCURACY; ADVANCED CANCER; BREAST CANCER; CANCER STAGING; CHEMOSENSITIVITY; CLASSIFIER; DRUG MECHANISM; DRUG TARGETING; EGFR GENE; GENE EXPRESSION PROFILING; GENETIC DATABASE; HUMAN; INTERMETHOD COMPARISON; LUNG CANCER; LUNG NON SMALL CELL CANCER; METASTASIS; MICROARRAY ANALYSIS; MOLECULAR DYNAMICS; MOLECULAR INTERACTION; MOLECULAR PATHOLOGY; ONCOGENE; PREDICTION; PRIORITY JOURNAL; PROCESS DEVELOPMENT; PROCESS OPTIMIZATION; PROGNOSIS; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SEQUENCE ANALYSIS; VALIDATION PROCESS;

BIOLOGICAL ASSAY; BIOMEDICAL RESEARCH; BREAST NEOPLASMS; FEMALE; GENE EXPRESSION PROFILING; HUMANS; TRANSLATIONAL MEDICAL RESEARCH; TUMOR MARKERS, BIOLOGICAL;

EID: 84655161546     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2011.125     Document Type: Review

References (67)

1. No authors listed Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365, 1687-1717 (2005).
2. Weigel, M. T. & Dowsett, M. Current and emerging biomarkers in breast cancer: prognosis and prediction. Endocr. Relat. Cancer 17, R245-R262 (2010).
3. Weigelt, B., Baehner, F. L. & Reis-Filho, J. S. The contribution of gene expression profiling to breast cancer classification, prognostication and prediction: a retrospective of the last decade. J. Pathol. 220, 263-280 (2010).
4. Sotiriou, C. & Pusztai, L. Gene-expression signatures in breast cancer. N. Engl. J. Med. 360, 790-800 (2009).
5. Reis-Filho, J. S., Weigelt, B., Fumagalli, D. & Sotiriou, C. Molecular profiling: moving away from tumor philately. Sci. Transl. Med. 2, 47ps43 (2010).
6. Perou, C. M. et al. Molecular portraits of human breast tumours. Nature 406, 747-752 (2000).
7. Sørlie, T. et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl Acad. Sci. USA 98, 10869-10874 (2001). (Pubitemid 32878711)
8. Sørlie, T. et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc. Natl Acad. Sci. USA 100, 8418-8423 (2003). (Pubitemid 36842560)
9. Hu, Z. et al. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics 7, 96 (2006).
10. Iwamoto, T. & Pusztai, L. Predicting prognosis of breast cancer with gene signatures: are we lost in a sea of data? Genome Med. 2, 81 (2010).
11. Prat, A. et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res. 12, R68 (2010).
12. Alizadeh, A. A. et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403, 503-511 (2000). (Pubitemid 30082188)
13. Yeoh, E. J. et al. Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell 1, 133-143 (2002).
14. Bhattacharjee, A. et al. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc. Natl Acad. Sci. USA 98, 13790-13795 (2001). (Pubitemid 33115977)
15. Garber, M. E. et al. Diversity of gene expression in adenocarcinoma of the lung. Proc. Natl Acad. Sci. USA 98, 13784-13789 (2001). (Pubitemid 33115976)
16. Beer, D. G. et al. Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat. Med. 8, 816-824 (2002).
17. Hayes, D. N. et al. Gene expression profiling reveals reproducible human lung adenocarcinoma subtypes in multiple independent patient cohorts. J. Clin. Oncol. 24, 5079-5090 (2006). (Pubitemid 46631412)
18. Janku, F., Stewart, D. J. & Kurzrock, R. Targeted therapy in non-small-cell lung cancer-is it becoming a reality? Nat. Rev. Clin. Oncol. 7, 401-414 (2010).
19. Davies, M. A. & Samuels, Y. Analysis of the genome to personalize therapy for melanoma. Oncogene 29, 5545-5555 (2010).
20. Paik, S. et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med. 351, 2817-2826 (2004). (Pubitemid 40051905)
21. van 't Veer, L. J. et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 415, 530-536 (2002).
22. Oakman, C., Santarpia, L. & Di Leo, A. Breast cancer assessment tools and optimizing adjuvant therapy. Nat. Rev. Clin. Oncol. 7, 725-732 (2010).
23. Cuzick, J. et al. Prognostic value of a combined, ER, PgR, Ki67, HER2 immunohistochemical (IHC4) score and comparison with the GHI Recurrence Score-Results from TransATAC abstract. Cancer Res. 69 (Suppl. 3), a74 (2009).
24. Viale, G. et al. Central Review of, ER, PgR and HER2 in BIG 1-98 Evaluating letrozole vs. letrozole followed by tamoxifen vs. tamoxifen followed by letrozole as adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive breast cancer abstract. Cancer Res. 69 (Suppl. 3), a76 (2009).
25. Borst, P. & Wessels, L. Do predictive signatures really predict response to cancer chemotherapy? Cell Cycle 9, 4836-4840 (2010).
26. Baggerly, K. A. & Coombes, K. R. Deriving chemosensitivity from cell lines: Forensic bioinformatics and reproducible research in high-throughput biology. Ann. Appl. Stat. 3, 1309-1334 (2009).
27. Liedtke, C. et al. Clinical evaluation of chemotherapy response predictors developed from breast cancer cell lines. Breast Cancer Res. Treat. 121, 301-309 (2010).
28. Popovici, V. et al. Effect of training-sample size and classification difficulty on the accuracy of genomic predictors. Breast Cancer Res. 12, R5 (2010).
29. Coombes, K. R., Wang, J. & Baggerly, K. A. Microarrays: retracing steps. Nat. Med. 13, 1276-1277 (2007).
30. Gruvberger, S. et al. Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns. Cancer Res. 61, 5979-5984 (2001). (Pubitemid 32762524)
31. Desmedt, C. et al. Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin. Cancer Res. 14, 5158-5165 (2008).
32. Wirapati, P. et al. Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res. 10, R65 (2008).
33. Weigelt, B. et al. Breast cancer molecular profiling with single sample predictors: a retrospective analysis. Lancet Oncol. 11, 339-349 (2010).
34. Haibe-Kains, B. et al. Robustness of breast cancer molecular subtypes identification abstract a980. Ann. Oncol. 21 (Suppl. 4), iv49-iv59 (2010).
35. Parker, J. S. et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J. Clin. Oncol. 27, 1160-1167 (2009).
36. de Ronde, J. J. et al. Concordance of clinical and molecular breast cancer subtyping in the context of preoperative chemotherapy response. Breast Cancer Res. Treat. 119, 119-126 (2010).
37. Cleator, S. J. et al. The effect of the stromal component of breast tumours on prediction of clinical outcome using gene expression microarray analysis. Breast Cancer Res. 8, R32 (2006).
38. Pusztai, L., Mazouni, C., Anderson, K., Wu, Y. & Symmans, W. F. Molecular classification of breast cancer: limitations and potential. Oncologist 11, 868-877 (2006). (Pubitemid 44373759)
39. Simon, R., Radmacher, M. D., Dobbin, K. & McShane, L. M. Pitfalls in the use of DNA microarray data for diagnostic and prognostic classification. J. Natl Cancer Inst. 95, 14-18 (2003). (Pubitemid 36124291)
40. Mackay, A. et al. Microarray-based class discovery for molecular classification of breast cancer: analysis of interobserver agreement. J. Natl Cancer Inst. 103, 662-673 (2011).
41. Wang, Y. et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365, 671-679 (2005). (Pubitemid 40260888)
42. Mook, S. et al. Calibration and discriminatory accuracy of prognosis calculation for breast cancer with the online Adjuvant! program: a hospital-based retrospective cohort study. Lancet Oncol. 10, 1070-1076 (2009).
43. Weigelt, B. & Reis-Filho, J. S. Molecular profiling currently offers no more than tumour morphology and basic immunohistochemistry. Breast Cancer Res. 12 (Suppl. 4), S5 (2010).
44. Rody, A. et al. T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers. Breast Cancer Res. 11, R15 (2009).
45. Teschendorff, A. E. & Caldas, C. A robust classifier of high predictive value to identify good prognosis patients in ER-negative breast cancer. Breast Cancer Res. 10, R73 (2008).
46. Rhodes, A., Jasani, B., Balaton, A. J. & Miller, K. D. Immunohistochemical demonstration of oestrogen and progesterone receptors: correlation of standards achieved on in house tumours with that achieved on external quality assessment material in over 150 laboratories from 26 countries. J. Clin. Pathol. 53, 292-301 (2000). (Pubitemid 30180402)
47. Badve, S. S. et al. Estrogen-and progesterone-receptor status in ECOG 2197: comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratory. J. Clin. Oncol. 26, 2473-2481 (2008).
48. Shi, L. et al. The MicroArray Quality Control (MAQC) project shows inter-and intraplatform reproducibility of gene expression measurements. Nat. Biotechnol. 24, 1151-1161 (2006). (Pubitemid 44359727)
49. Shi, L. et al. The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models. Nat. Biotechnol. 28, 827-838 (2010).
50. Bueno-de-Mesquita, J. M. et al. Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER). Lancet Oncol. 8, 1079-1087 (2007).
51. Bonnefoi, H., Underhill, C., Iggo, R. & Cameron, D. Predictive signatures for chemotherapy sensitivity in breast cancer: are they ready for use in the clinic? Eur. J. Cancer 45, 1733-1743 (2009).
52. Hess, K. R. et al. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J. Clin. Oncol. 24, 4236-4244 (2006). (Pubitemid 46630780)
53. Tabchy, A. et al. Evaluation of a 30-gene paclitaxel, fluorouracil, doxorubicin, and cyclophosphamide chemotherapy response predictor in a multicenter randomized trial in breast cancer. Clin. Cancer Res. 16, 5351-5361 (2010).
54. Ding, L. et al. Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature 464, 999-1005 (2010).
55. Shah, S. P. et al. Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature 461, 809-813 (2009).
56. Esteva, F. J., Yu, D., Hung, M. C. & Hortobagyi, G. N. Molecular predictors of response to trastuzumab and lapatinib in breast cancer. Nat. Rev. Clin. Oncol. 7, 98-107 (2010).
57. Aparicio, S. A. & Huntsman, D. G. Does massively parallel DNA resequencing signify the end of histopathology as we know it? J. Pathol. 220, 307-315 (2010).
58. Stephens, P. J. et al. Complex landscapes of somatic rearrangement in human breast cancer genomes. Nature 462, 1005-1010 (2009).
59. Ahmed, A. A. & Brenton, J. D. Microarrays and breast cancer clinical studies: forgetting what we have not yet learnt. Breast Cancer Res. 7, 96-99 (2005). (Pubitemid 40704128)
60. Evans, J. P., Meslin, E. M., Marteau, T. M. & Caulfield, T. Genomics. Deflating the genomic bubble. Science 331, 861-862 (2011).
61. Ashworth, A., Lord, C. J. & Reis-Filho, J. S. Genetic interactions in cancer progression and treatment. Cell 145, 30-38 (2011).
62. Dowsett, M. et al. Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. J. Natl Cancer Inst. 99, 167-170 (2007).
63. Graeser, M. et al. A marker of homologous recombination predicts pathologic complete response to neoadjuvant chemotherapy in primary breast cancer. Clin. Cancer Res. 16, 6159-6168 (2010).
64. Ashworth, A. & Bernards, R. Using functional genetics to understand breast cancer biology. Cold Spring Harb. Perspect. Biol. 2, a003327 (2010).
65. Villarroel, M. C. et al. Personalizing cancer treatment in the age of global genomic analyses: PALB2 gene mutations and the response to DNA damaging agents in pancreatic cancer. Mol. Cancer Ther. 10, 3-8 (2011).
66. Barretina, J. et al. Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nat. Genet. 42, 715-721 (2010).
67. Haber, D. A., Gray, N. S. & Baselga, J. The evolving war on cancer. Cell 145, 19-24 (2011).